New oxygen drug NanO2 tested in patients at risk of ventilator
NCT ID NCT06658535
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a drug called NanO2, which is designed to carry oxygen in the blood. It is being given to 18 hospitalized patients with mild respiratory distress who need extra oxygen but are not yet on a breathing machine. The main goal is to find the safest dose and check for side effects, with a future study planned if this goes well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NanO2 (dodecafluoropentane)
- What this could lead to
- If successful, this could lead to a new way to deliver oxygen to patients with mild breathing problems, potentially reducing the need for mechanical ventilation.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, focused on safety and dosing. It is too small to prove effectiveness, and the treatment may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD RESPIRATORY DISTRESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grey Nun Community Hospital
RECRUITINGEdmonton, Alberta, T6L 5X8, Canada
-
Hôpital Maisonneuve Rosemont
RECRUITINGMontreal, Quebec, H1T 2M4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.